nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—CYP19A1—Betamethasone—psoriasis	0.089	0.148	CbGbCtD
Mefloquine—BCHE—Triamcinolone—psoriasis	0.0865	0.144	CbGbCtD
Mefloquine—CYP19A1—Dexamethasone—psoriasis	0.0518	0.0862	CbGbCtD
Mefloquine—CYP2D6—Hydroxyurea—psoriasis	0.0394	0.0655	CbGbCtD
Mefloquine—HBA2—dermis—psoriasis	0.0362	0.59	CbGeAlD
Mefloquine—CYP3A4—Calcitriol—psoriasis	0.0294	0.049	CbGbCtD
Mefloquine—CYP2D6—Cholecalciferol—psoriasis	0.0238	0.0397	CbGbCtD
Mefloquine—CYP3A4—Methoxsalen—psoriasis	0.0229	0.0381	CbGbCtD
Mefloquine—ABCB1—Mycophenolate mofetil—psoriasis	0.0219	0.0365	CbGbCtD
Mefloquine—ABCB1—Betamethasone—psoriasis	0.0188	0.0313	CbGbCtD
Mefloquine—ABCB1—Prednisolone—psoriasis	0.0186	0.0309	CbGbCtD
Mefloquine—ABCB1—Hydrocortisone—psoriasis	0.0176	0.0293	CbGbCtD
Mefloquine—ABCB1—Prednisone—psoriasis	0.0175	0.0292	CbGbCtD
Mefloquine—ABCB1—Cyclosporine—psoriasis	0.0166	0.0277	CbGbCtD
Mefloquine—CYP2D6—Cyclosporine—psoriasis	0.0157	0.0261	CbGbCtD
Mefloquine—CYP3A4—Cholecalciferol—psoriasis	0.0152	0.0252	CbGbCtD
Mefloquine—CYP3A4—Triamcinolone—psoriasis	0.0131	0.0219	CbGbCtD
Mefloquine—CYP3A4—Mycophenolate mofetil—psoriasis	0.0131	0.0219	CbGbCtD
Mefloquine—CYP3A4—Betamethasone—psoriasis	0.0113	0.0188	CbGbCtD
Mefloquine—CYP3A4—Prednisolone—psoriasis	0.0111	0.0185	CbGbCtD
Mefloquine—HBA2—endothelium—psoriasis	0.011	0.18	CbGeAlD
Mefloquine—ABCB1—Dexamethasone—psoriasis	0.011	0.0182	CbGbCtD
Mefloquine—CYP3A4—Hydrocortisone—psoriasis	0.0106	0.0176	CbGbCtD
Mefloquine—CYP3A4—Prednisone—psoriasis	0.0105	0.0175	CbGbCtD
Mefloquine—CYP2D6—Dexamethasone—psoriasis	0.0103	0.0172	CbGbCtD
Mefloquine—CYP3A4—Cyclosporine—psoriasis	0.00996	0.0166	CbGbCtD
Mefloquine—ABCB1—Methotrexate—psoriasis	0.0088	0.0146	CbGbCtD
Mefloquine—CYP3A4—Dexamethasone—psoriasis	0.00656	0.0109	CbGbCtD
Mefloquine—HBA1—skin of body—psoriasis	0.00513	0.0837	CbGeAlD
Mefloquine—HBA2—skin of body—psoriasis	0.00471	0.0769	CbGeAlD
Mefloquine—ADORA1—tendon—psoriasis	0.00161	0.0263	CbGeAlD
Mefloquine—ACHE—tendon—psoriasis	0.0016	0.0261	CbGeAlD
Mefloquine—HBA1—Vitamin B12 Metabolism—IFNG—psoriasis	0.00125	0.0151	CbGpPWpGaD
Mefloquine—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00122	0.0146	CbGpPWpGaD
Mefloquine—CYP19A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.0012	0.0144	CbGpPWpGaD
Mefloquine—ACHE—ATF-2 transcription factor network—IL23A—psoriasis	0.0012	0.0144	CbGpPWpGaD
Mefloquine—HBA1—Selenium Micronutrient Network—CRP—psoriasis	0.00116	0.0139	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—IL22—psoriasis	0.00111	0.0134	CbGpPWpGaD
Mefloquine—HBA1—Selenium Micronutrient Network—ICAM1—psoriasis	0.00106	0.0128	CbGpPWpGaD
Mefloquine—HBA1—Vitamin B12 Metabolism—NFKB1—psoriasis	0.00104	0.0125	CbGpPWpGaD
Mefloquine—BCHE—skin of body—psoriasis	0.00103	0.0169	CbGeAlD
Mefloquine—HBA1—Folate Metabolism—IFNG—psoriasis	0.00102	0.0123	CbGpPWpGaD
Mefloquine—CYP19A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000986	0.0119	CbGpPWpGaD
Mefloquine—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000854	0.0103	CbGpPWpGaD
Mefloquine—ACHE—Synthesis, secretion, and deacylation of Ghrelin—LEP—psoriasis	0.000847	0.0102	CbGpPWpGaD
Mefloquine—HBA1—Folate Metabolism—NFKB1—psoriasis	0.000847	0.0102	CbGpPWpGaD
Mefloquine—HBA1—Vitamin B12 Metabolism—TNF—psoriasis	0.000809	0.00975	CbGpPWpGaD
Mefloquine—HBA1—Selenium Micronutrient Network—IFNG—psoriasis	0.000808	0.00973	CbGpPWpGaD
Mefloquine—ADORA1—G alpha (i) signalling events—HCAR2—psoriasis	0.000796	0.00958	CbGpPWpGaD
Mefloquine—BCHE—Synthesis, secretion, and deacylation of Ghrelin—LEP—psoriasis	0.000755	0.00909	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—NDUFA5—psoriasis	0.000752	0.00906	CbGpPWpGaD
Mefloquine—HBA1—Selenium Micronutrient Network—NFKB1—psoriasis	0.000673	0.0081	CbGpPWpGaD
Mefloquine—HBA1—Folate Metabolism—TNF—psoriasis	0.000659	0.00793	CbGpPWpGaD
Mefloquine—HBA1—Vitamin B12 Metabolism—IL6—psoriasis	0.000653	0.00786	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—CYP2S1—psoriasis	0.00064	0.0077	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000633	0.00762	CbGpPWpGaD
Mefloquine—ACHE—Peptide hormone metabolism—REN—psoriasis	0.000603	0.00726	CbGpPWpGaD
Mefloquine—CYP19A1—Ovarian Infertility Genes—VDR—psoriasis	0.000586	0.00706	CbGpPWpGaD
Mefloquine—HBA1—Folate Metabolism—TP53—psoriasis	0.000581	0.00699	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—NDUFA5—psoriasis	0.00057	0.00686	CbGpPWpGaD
Mefloquine—ACHE—Melatonin metabolism and effects—APOE—psoriasis	0.000552	0.00665	CbGpPWpGaD
Mefloquine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000543	0.00653	CbGpPWpGaD
Mefloquine—BCHE—Peptide hormone metabolism—REN—psoriasis	0.000538	0.00647	CbGpPWpGaD
Mefloquine—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000536	0.00645	CbGpPWpGaD
Mefloquine—HBA1—Folate Metabolism—IL6—psoriasis	0.000531	0.0064	CbGpPWpGaD
Mefloquine—CYP19A1—Biological oxidations—CYP2S1—psoriasis	0.000524	0.0063	CbGpPWpGaD
Mefloquine—HBA1—Selenium Micronutrient Network—TNF—psoriasis	0.000523	0.0063	CbGpPWpGaD
Mefloquine—CYP19A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000516	0.00622	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000489	0.00588	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—CYP2S1—psoriasis	0.000485	0.00584	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—HCAR2—psoriasis	0.000482	0.0058	CbGpPWpGaD
Mefloquine—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000461	0.00554	CbGpPWpGaD
Mefloquine—CYP19A1—Tryptophan metabolism—CAT—psoriasis	0.000452	0.00544	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.00044	0.0053	CbGpPWpGaD
Mefloquine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00044	0.0053	CbGpPWpGaD
Mefloquine—HBA1—Selenium Micronutrient Network—IL6—psoriasis	0.000422	0.00508	CbGpPWpGaD
Mefloquine—ADORA1—G alpha (i) signalling events—CCL20—psoriasis	0.000413	0.00498	CbGpPWpGaD
Mefloquine—ACHE—Peptide hormone metabolism—ACE—psoriasis	0.000376	0.00453	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—HCAR2—psoriasis	0.000372	0.00448	CbGpPWpGaD
Mefloquine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000355	0.00427	CbGpPWpGaD
Mefloquine—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00035	0.00422	CbGpPWpGaD
Mefloquine—BCHE—Peptide hormone metabolism—ACE—psoriasis	0.000336	0.00404	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000333	0.00401	CbGpPWpGaD
Mefloquine—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—psoriasis	0.000329	0.00396	CbGpPWpGaD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000329	0.00396	CbGpPWpGaD
Mefloquine—ACHE—Melatonin metabolism and effects—NFKB1—psoriasis	0.000328	0.00395	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—CARM1—psoriasis	0.000312	0.00376	CbGpPWpGaD
Mefloquine—ADORA2A—Monoamine Transport—TNF—psoriasis	0.000296	0.00356	CbGpPWpGaD
Mefloquine—ACHE—ATF-2 transcription factor network—NOS2—psoriasis	0.000292	0.00351	CbGpPWpGaD
Mefloquine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000288	0.00346	CbGpPWpGaD
Mefloquine—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000284	0.00342	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000273	0.00329	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—HCAR2—psoriasis	0.000272	0.00328	CbGpPWpGaD
Mefloquine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000265	0.00318	CbGpPWpGaD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000254	0.00305	CbGpPWpGaD
Mefloquine—ADORA1—GPCR ligand binding—CCL20—psoriasis	0.00025	0.00301	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—HCAR2—psoriasis	0.000247	0.00298	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—CARM1—psoriasis	0.000237	0.00285	CbGpPWpGaD
Mefloquine—ACHE—Monoamine Transport—TNF—psoriasis	0.000236	0.00284	CbGpPWpGaD
Mefloquine—ACHE—Peptide hormone metabolism—LEP—psoriasis	0.000234	0.00281	CbGpPWpGaD
Mefloquine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000234	0.00281	CbGpPWpGaD
Mefloquine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.00023	0.00277	CbGpPWpGaD
Mefloquine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000227	0.00273	CbGpPWpGaD
Mefloquine—ACHE—ATF-2 transcription factor network—IFNG—psoriasis	0.000224	0.00269	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000211	0.00254	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—HCAR2—psoriasis	0.00021	0.00253	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—IL13—psoriasis	0.00021	0.00252	CbGpPWpGaD
Mefloquine—BCHE—Peptide hormone metabolism—LEP—psoriasis	0.000208	0.00251	CbGpPWpGaD
Mefloquine—ACHE—ATF-2 transcription factor network—CXCL8—psoriasis	0.000208	0.0025	CbGpPWpGaD
Mefloquine—ACHE—ATF-2 transcription factor network—JUN—psoriasis	0.000193	0.00233	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—CCL20—psoriasis	0.000193	0.00233	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000193	0.00232	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—CAT—psoriasis	0.000192	0.00231	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—HCAR2—psoriasis	0.000191	0.0023	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—LEP—psoriasis	0.00019	0.00229	CbGpPWpGaD
Mefloquine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000184	0.00222	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000179	0.00216	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—NOS2—psoriasis	0.000177	0.00214	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000175	0.00211	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—PPARG—psoriasis	0.000166	0.002	CbGpPWpGaD
Mefloquine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000163	0.00196	CbGpPWpGaD
Mefloquine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000153	0.00184	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000151	0.00181	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—APOE—psoriasis	0.000149	0.0018	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—LEP—psoriasis	0.000147	0.00177	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HCAR2—psoriasis	0.000146	0.00176	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—CAT—psoriasis	0.000146	0.00175	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000145	0.00174	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—CCL20—psoriasis	0.000141	0.0017	CbGpPWpGaD
Mefloquine—Mental disorder—Prednisone—psoriasis	0.000139	0.000547	CcSEcCtD
Mefloquine—Malnutrition—Prednisone—psoriasis	0.000138	0.000543	CcSEcCtD
Mefloquine—Erythema—Prednisone—psoriasis	0.000138	0.000543	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000138	0.000543	CcSEcCtD
Mefloquine—Hyperhidrosis—Triamcinolone—psoriasis	0.000138	0.000542	CcSEcCtD
Mefloquine—Agranulocytosis—Methotrexate—psoriasis	0.000138	0.000542	CcSEcCtD
Mefloquine—Convulsion—Dexamethasone—psoriasis	0.000138	0.000541	CcSEcCtD
Mefloquine—Convulsion—Betamethasone—psoriasis	0.000138	0.000541	CcSEcCtD
Mefloquine—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000137	0.000539	CcSEcCtD
Mefloquine—Insomnia—Hydrocortisone—psoriasis	0.000137	0.000539	CcSEcCtD
Mefloquine—Hypertension—Dexamethasone—psoriasis	0.000137	0.000539	CcSEcCtD
Mefloquine—Hypertension—Betamethasone—psoriasis	0.000137	0.000539	CcSEcCtD
Mefloquine—ADORA2A—Circadian rythm related genes—NOS2—psoriasis	0.000137	0.00165	CbGpPWpGaD
Mefloquine—Paraesthesia—Hydrocortisone—psoriasis	0.000136	0.000535	CcSEcCtD
Mefloquine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000136	0.000535	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000136	0.00163	CbGpPWpGaD
Mefloquine—Urticaria—Cyclosporine—psoriasis	0.000136	0.000533	CcSEcCtD
Mefloquine—Myalgia—Dexamethasone—psoriasis	0.000135	0.000531	CcSEcCtD
Mefloquine—Myalgia—Betamethasone—psoriasis	0.000135	0.000531	CcSEcCtD
Mefloquine—Body temperature increased—Cyclosporine—psoriasis	0.000135	0.00053	CcSEcCtD
Mefloquine—Abdominal pain—Cyclosporine—psoriasis	0.000135	0.00053	CcSEcCtD
Mefloquine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.000135	0.00162	CbGpPWpGaD
Mefloquine—Anxiety—Betamethasone—psoriasis	0.000135	0.000529	CcSEcCtD
Mefloquine—Anxiety—Dexamethasone—psoriasis	0.000135	0.000529	CcSEcCtD
Mefloquine—Vomiting—Mycophenolic acid—psoriasis	0.000134	0.000527	CcSEcCtD
Mefloquine—Discomfort—Betamethasone—psoriasis	0.000134	0.000525	CcSEcCtD
Mefloquine—Discomfort—Dexamethasone—psoriasis	0.000134	0.000525	CcSEcCtD
Mefloquine—Dyspepsia—Hydrocortisone—psoriasis	0.000134	0.000525	CcSEcCtD
Mefloquine—Rash—Mycophenolic acid—psoriasis	0.000133	0.000523	CcSEcCtD
Mefloquine—Dermatitis—Mycophenolic acid—psoriasis	0.000133	0.000522	CcSEcCtD
Mefloquine—Urticaria—Mycophenolate mofetil—psoriasis	0.000132	0.00052	CcSEcCtD
Mefloquine—Headache—Mycophenolic acid—psoriasis	0.000132	0.000519	CcSEcCtD
Mefloquine—Decreased appetite—Hydrocortisone—psoriasis	0.000132	0.000518	CcSEcCtD
Mefloquine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000132	0.00159	CbGpPWpGaD
Mefloquine—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000132	0.000517	CcSEcCtD
Mefloquine—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000132	0.000517	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—IL10—psoriasis	0.000131	0.00158	CbGpPWpGaD
Mefloquine—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000131	0.000514	CcSEcCtD
Mefloquine—Fatigue—Hydrocortisone—psoriasis	0.000131	0.000514	CcSEcCtD
Mefloquine—Vision blurred—Prednisone—psoriasis	0.00013	0.000512	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.00013	0.000511	CcSEcCtD
Mefloquine—HBA2—Metabolism—PPARG—psoriasis	0.00013	0.00157	CbGpPWpGaD
Mefloquine—Anaphylactic shock—Betamethasone—psoriasis	0.00013	0.000509	CcSEcCtD
Mefloquine—Oedema—Dexamethasone—psoriasis	0.00013	0.000509	CcSEcCtD
Mefloquine—Oedema—Betamethasone—psoriasis	0.00013	0.000509	CcSEcCtD
Mefloquine—Anaphylactic shock—Dexamethasone—psoriasis	0.00013	0.000509	CcSEcCtD
Mefloquine—Insomnia—Triamcinolone—psoriasis	0.000129	0.000508	CcSEcCtD
Mefloquine—ADORA1—Signaling by GPCR—CCL20—psoriasis	0.000128	0.00155	CbGpPWpGaD
Mefloquine—Ill-defined disorder—Prednisone—psoriasis	0.000128	0.000504	CcSEcCtD
Mefloquine—Paraesthesia—Triamcinolone—psoriasis	0.000128	0.000504	CcSEcCtD
Mefloquine—ADORA2A—Circadian rythm related genes—PPARG—psoriasis	0.000128	0.00154	CbGpPWpGaD
Mefloquine—Feeling abnormal—Prednisolone—psoriasis	0.000128	0.000503	CcSEcCtD
Mefloquine—Visual impairment—Methotrexate—psoriasis	0.000128	0.000503	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—IL4—psoriasis	0.000128	0.00154	CbGpPWpGaD
Mefloquine—Shock—Betamethasone—psoriasis	0.000127	0.000501	CcSEcCtD
Mefloquine—Shock—Dexamethasone—psoriasis	0.000127	0.000501	CcSEcCtD
Mefloquine—Dyspnoea—Triamcinolone—psoriasis	0.000127	0.0005	CcSEcCtD
Mefloquine—Nervous system disorder—Dexamethasone—psoriasis	0.000127	0.000499	CcSEcCtD
Mefloquine—Nervous system disorder—Betamethasone—psoriasis	0.000127	0.000499	CcSEcCtD
Mefloquine—Agitation—Prednisone—psoriasis	0.000127	0.000499	CcSEcCtD
Mefloquine—Thrombocytopenia—Betamethasone—psoriasis	0.000127	0.000499	CcSEcCtD
Mefloquine—Thrombocytopenia—Dexamethasone—psoriasis	0.000127	0.000499	CcSEcCtD
Mefloquine—ADORA1—Signaling Pathways—TAGAP—psoriasis	0.000127	0.00152	CbGpPWpGaD
Mefloquine—Tachycardia—Dexamethasone—psoriasis	0.000126	0.000497	CcSEcCtD
Mefloquine—Tachycardia—Betamethasone—psoriasis	0.000126	0.000497	CcSEcCtD
Mefloquine—Hypersensitivity—Cyclosporine—psoriasis	0.000126	0.000494	CcSEcCtD
Mefloquine—Dyspepsia—Triamcinolone—psoriasis	0.000126	0.000494	CcSEcCtD
Mefloquine—Erythema multiforme—Methotrexate—psoriasis	0.000126	0.000493	CcSEcCtD
Mefloquine—Nausea—Mycophenolic acid—psoriasis	0.000125	0.000492	CcSEcCtD
Mefloquine—Hyperhidrosis—Betamethasone—psoriasis	0.000125	0.000492	CcSEcCtD
Mefloquine—Hyperhidrosis—Dexamethasone—psoriasis	0.000125	0.000492	CcSEcCtD
Mefloquine—Feeling abnormal—Hydrocortisone—psoriasis	0.000125	0.000491	CcSEcCtD
Mefloquine—Malaise—Prednisone—psoriasis	0.000125	0.00049	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—HLA-B—psoriasis	0.000125	0.0015	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000125	0.0015	CbGpPWpGaD
Mefloquine—Vertigo—Prednisone—psoriasis	0.000124	0.000488	CcSEcCtD
Mefloquine—Eye disorder—Methotrexate—psoriasis	0.000124	0.000487	CcSEcCtD
Mefloquine—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000124	0.000487	CcSEcCtD
Mefloquine—Syncope—Prednisone—psoriasis	0.000124	0.000487	CcSEcCtD
Mefloquine—Tinnitus—Methotrexate—psoriasis	0.000124	0.000486	CcSEcCtD
Mefloquine—Urticaria—Prednisolone—psoriasis	0.000123	0.000485	CcSEcCtD
Mefloquine—Cardiac disorder—Methotrexate—psoriasis	0.000123	0.000484	CcSEcCtD
Mefloquine—Fatigue—Triamcinolone—psoriasis	0.000123	0.000484	CcSEcCtD
Mefloquine—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000123	0.000482	CcSEcCtD
Mefloquine—Asthenia—Cyclosporine—psoriasis	0.000122	0.000481	CcSEcCtD
Mefloquine—Loss of consciousness—Prednisone—psoriasis	0.000122	0.000478	CcSEcCtD
Mefloquine—Hypotension—Dexamethasone—psoriasis	0.000121	0.000476	CcSEcCtD
Mefloquine—Hypotension—Betamethasone—psoriasis	0.000121	0.000476	CcSEcCtD
Mefloquine—Pruritus—Cyclosporine—psoriasis	0.000121	0.000474	CcSEcCtD
Mefloquine—Urticaria—Hydrocortisone—psoriasis	0.00012	0.000473	CcSEcCtD
Mefloquine—Angiopathy—Methotrexate—psoriasis	0.00012	0.000473	CcSEcCtD
Mefloquine—Body temperature increased—Hydrocortisone—psoriasis	0.00012	0.000471	CcSEcCtD
Mefloquine—Abdominal pain—Hydrocortisone—psoriasis	0.00012	0.000471	CcSEcCtD
Mefloquine—Convulsion—Prednisone—psoriasis	0.00012	0.000471	CcSEcCtD
Mefloquine—Mediastinal disorder—Methotrexate—psoriasis	0.00012	0.00047	CcSEcCtD
Mefloquine—Asthenia—Mycophenolate mofetil—psoriasis	0.000119	0.000469	CcSEcCtD
Mefloquine—Hypertension—Prednisone—psoriasis	0.000119	0.000469	CcSEcCtD
Mefloquine—Chills—Methotrexate—psoriasis	0.000119	0.000468	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000118	0.000464	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000118	0.000464	CcSEcCtD
Mefloquine—Pruritus—Mycophenolate mofetil—psoriasis	0.000118	0.000463	CcSEcCtD
Mefloquine—Arthralgia—Prednisone—psoriasis	0.000118	0.000463	CcSEcCtD
Mefloquine—Myalgia—Prednisone—psoriasis	0.000118	0.000463	CcSEcCtD
Mefloquine—Feeling abnormal—Triamcinolone—psoriasis	0.000118	0.000462	CcSEcCtD
Mefloquine—ADORA1—Circadian rythm related genes—JUN—psoriasis	0.000118	0.00142	CbGpPWpGaD
Mefloquine—Anxiety—Prednisone—psoriasis	0.000117	0.000461	CcSEcCtD
Mefloquine—Alopecia—Methotrexate—psoriasis	0.000117	0.000461	CcSEcCtD
Mefloquine—Insomnia—Dexamethasone—psoriasis	0.000117	0.00046	CcSEcCtD
Mefloquine—Insomnia—Betamethasone—psoriasis	0.000117	0.00046	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000117	0.000459	CcSEcCtD
Mefloquine—ACHE—ATF-2 transcription factor network—IL6—psoriasis	0.000117	0.00141	CbGpPWpGaD
Mefloquine—Diarrhoea—Cyclosporine—psoriasis	0.000117	0.000459	CcSEcCtD
Mefloquine—Paraesthesia—Dexamethasone—psoriasis	0.000116	0.000457	CcSEcCtD
Mefloquine—Paraesthesia—Betamethasone—psoriasis	0.000116	0.000457	CcSEcCtD
Mefloquine—Discomfort—Prednisone—psoriasis	0.000116	0.000457	CcSEcCtD
Mefloquine—Mental disorder—Methotrexate—psoriasis	0.000116	0.000457	CcSEcCtD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000116	0.0014	CbGpPWpGaD
Mefloquine—Erythema—Methotrexate—psoriasis	0.000116	0.000454	CcSEcCtD
Mefloquine—Malnutrition—Methotrexate—psoriasis	0.000116	0.000454	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—HLA-A—psoriasis	0.000116	0.00139	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—NDUFA5—psoriasis	0.000115	0.00138	CbGpPWpGaD
Mefloquine—Hypersensitivity—Prednisolone—psoriasis	0.000114	0.00045	CcSEcCtD
Mefloquine—Dyspepsia—Dexamethasone—psoriasis	0.000114	0.000448	CcSEcCtD
Mefloquine—Dyspepsia—Betamethasone—psoriasis	0.000114	0.000448	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	0.000114	0.00137	CbGpPWpGaD
Mefloquine—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000114	0.000448	CcSEcCtD
Mefloquine—ACHE—Metabolism of proteins—REN—psoriasis	0.000114	0.00137	CbGpPWpGaD
Mefloquine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000114	0.00137	CbGpPWpGaD
Mefloquine—Urticaria—Triamcinolone—psoriasis	0.000113	0.000446	CcSEcCtD
Mefloquine—HBA1—Metabolism—APOE—psoriasis	0.000113	0.00136	CbGpPWpGaD
Mefloquine—Body temperature increased—Triamcinolone—psoriasis	0.000113	0.000444	CcSEcCtD
Mefloquine—Dizziness—Cyclosporine—psoriasis	0.000113	0.000443	CcSEcCtD
Mefloquine—Oedema—Prednisone—psoriasis	0.000113	0.000443	CcSEcCtD
Mefloquine—Anaphylactic shock—Prednisone—psoriasis	0.000113	0.000443	CcSEcCtD
Mefloquine—ADORA2A—Signaling Pathways—HCAR2—psoriasis	0.000113	0.00136	CbGpPWpGaD
Mefloquine—Decreased appetite—Dexamethasone—psoriasis	0.000113	0.000443	CcSEcCtD
Mefloquine—Decreased appetite—Betamethasone—psoriasis	0.000113	0.000443	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000112	0.00044	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Betamethasone—psoriasis	0.000112	0.00044	CcSEcCtD
Mefloquine—Hypersensitivity—Hydrocortisone—psoriasis	0.000112	0.000439	CcSEcCtD
Mefloquine—Fatigue—Betamethasone—psoriasis	0.000112	0.000439	CcSEcCtD
Mefloquine—Fatigue—Dexamethasone—psoriasis	0.000112	0.000439	CcSEcCtD
Mefloquine—ADORA1—G alpha (i) signalling events—CXCL8—psoriasis	0.000112	0.00134	CbGpPWpGaD
Mefloquine—Shock—Prednisone—psoriasis	0.000111	0.000436	CcSEcCtD
Mefloquine—Nervous system disorder—Prednisone—psoriasis	0.000111	0.000435	CcSEcCtD
Mefloquine—Tachycardia—Prednisone—psoriasis	0.00011	0.000433	CcSEcCtD
Mefloquine—Dizziness—Mycophenolate mofetil—psoriasis	0.00011	0.000433	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	0.00011	0.00132	CbGpPWpGaD
Mefloquine—Skin disorder—Prednisone—psoriasis	0.00011	0.000431	CcSEcCtD
Mefloquine—ADORA2A—GPCR downstream signaling—CCL20—psoriasis	0.000109	0.00131	CbGpPWpGaD
Mefloquine—Hyperhidrosis—Prednisone—psoriasis	0.000109	0.000429	CcSEcCtD
Mefloquine—Vision blurred—Methotrexate—psoriasis	0.000109	0.000428	CcSEcCtD
Mefloquine—Asthenia—Hydrocortisone—psoriasis	0.000109	0.000428	CcSEcCtD
Mefloquine—Vomiting—Cyclosporine—psoriasis	0.000109	0.000426	CcSEcCtD
Mefloquine—Rash—Cyclosporine—psoriasis	0.000108	0.000423	CcSEcCtD
Mefloquine—Dermatitis—Cyclosporine—psoriasis	0.000108	0.000422	CcSEcCtD
Mefloquine—Pruritus—Hydrocortisone—psoriasis	0.000107	0.000422	CcSEcCtD
Mefloquine—Ill-defined disorder—Methotrexate—psoriasis	0.000107	0.000421	CcSEcCtD
Mefloquine—Headache—Cyclosporine—psoriasis	0.000107	0.00042	CcSEcCtD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000107	0.00129	CbGpPWpGaD
Mefloquine—Feeling abnormal—Betamethasone—psoriasis	0.000107	0.00042	CcSEcCtD
Mefloquine—Feeling abnormal—Dexamethasone—psoriasis	0.000107	0.00042	CcSEcCtD
Mefloquine—Gastrointestinal pain—Dexamethasone—psoriasis	0.000106	0.000416	CcSEcCtD
Mefloquine—Gastrointestinal pain—Betamethasone—psoriasis	0.000106	0.000416	CcSEcCtD
Mefloquine—Vomiting—Mycophenolate mofetil—psoriasis	0.000106	0.000416	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	0.000106	0.00127	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—NDUFA5—psoriasis	0.000105	0.00127	CbGpPWpGaD
Mefloquine—Hypersensitivity—Triamcinolone—psoriasis	0.000105	0.000413	CcSEcCtD
Mefloquine—Rash—Mycophenolate mofetil—psoriasis	0.000105	0.000412	CcSEcCtD
Mefloquine—Dermatitis—Mycophenolate mofetil—psoriasis	0.000105	0.000412	CcSEcCtD
Mefloquine—Headache—Mycophenolate mofetil—psoriasis	0.000104	0.00041	CcSEcCtD
Mefloquine—Malaise—Methotrexate—psoriasis	0.000104	0.000409	CcSEcCtD
Mefloquine—Vertigo—Methotrexate—psoriasis	0.000104	0.000408	CcSEcCtD
Mefloquine—Diarrhoea—Hydrocortisone—psoriasis	0.000104	0.000408	CcSEcCtD
Mefloquine—Leukopenia—Methotrexate—psoriasis	0.000103	0.000406	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—NFKBIA—psoriasis	0.000103	0.00124	CbGpPWpGaD
Mefloquine—Urticaria—Betamethasone—psoriasis	0.000103	0.000404	CcSEcCtD
Mefloquine—Urticaria—Dexamethasone—psoriasis	0.000103	0.000404	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Prednisone—psoriasis	0.000103	0.000404	CcSEcCtD
Mefloquine—Dizziness—Prednisolone—psoriasis	0.000103	0.000403	CcSEcCtD
Mefloquine—Asthenia—Triamcinolone—psoriasis	0.000102	0.000403	CcSEcCtD
Mefloquine—Abdominal pain—Dexamethasone—psoriasis	0.000102	0.000402	CcSEcCtD
Mefloquine—Body temperature increased—Dexamethasone—psoriasis	0.000102	0.000402	CcSEcCtD
Mefloquine—Body temperature increased—Betamethasone—psoriasis	0.000102	0.000402	CcSEcCtD
Mefloquine—Abdominal pain—Betamethasone—psoriasis	0.000102	0.000402	CcSEcCtD
Mefloquine—BCHE—Metabolism—NDUFA5—psoriasis	0.000102	0.00123	CbGpPWpGaD
Mefloquine—Insomnia—Prednisone—psoriasis	0.000102	0.000401	CcSEcCtD
Mefloquine—BCHE—Metabolism of proteins—REN—psoriasis	0.000102	0.00122	CbGpPWpGaD
Mefloquine—Nausea—Cyclosporine—psoriasis	0.000101	0.000398	CcSEcCtD
Mefloquine—Paraesthesia—Prednisone—psoriasis	0.000101	0.000398	CcSEcCtD
Mefloquine—Pruritus—Triamcinolone—psoriasis	0.000101	0.000397	CcSEcCtD
Mefloquine—Dizziness—Hydrocortisone—psoriasis	0.0001	0.000394	CcSEcCtD
Mefloquine—Convulsion—Methotrexate—psoriasis	0.0001	0.000393	CcSEcCtD
Mefloquine—Dyspepsia—Prednisone—psoriasis	9.93e-05	0.00039	CcSEcCtD
Mefloquine—ADORA2A—Signaling by GPCR—CCL20—psoriasis	9.92e-05	0.00119	CbGpPWpGaD
Mefloquine—Nausea—Mycophenolate mofetil—psoriasis	9.89e-05	0.000389	CcSEcCtD
Mefloquine—HBA1—Metabolism—PPARG—psoriasis	9.86e-05	0.00119	CbGpPWpGaD
Mefloquine—Myalgia—Methotrexate—psoriasis	9.84e-05	0.000387	CcSEcCtD
Mefloquine—Arthralgia—Methotrexate—psoriasis	9.84e-05	0.000387	CcSEcCtD
Mefloquine—Chest pain—Methotrexate—psoriasis	9.84e-05	0.000387	CcSEcCtD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.82e-05	0.00118	CbGpPWpGaD
Mefloquine—Decreased appetite—Prednisone—psoriasis	9.81e-05	0.000385	CcSEcCtD
Mefloquine—Rash—Prednisolone—psoriasis	9.79e-05	0.000385	CcSEcCtD
Mefloquine—Dermatitis—Prednisolone—psoriasis	9.78e-05	0.000384	CcSEcCtD
Mefloquine—ADORA2A—Signaling Pathways—TAGAP—psoriasis	9.78e-05	0.00118	CbGpPWpGaD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.77e-05	0.000384	CcSEcCtD
Mefloquine—ACHE—Metabolism—CYP2S1—psoriasis	9.74e-05	0.00117	CbGpPWpGaD
Mefloquine—Fatigue—Prednisone—psoriasis	9.73e-05	0.000382	CcSEcCtD
Mefloquine—Headache—Prednisolone—psoriasis	9.73e-05	0.000382	CcSEcCtD
Mefloquine—Discomfort—Methotrexate—psoriasis	9.72e-05	0.000382	CcSEcCtD
Mefloquine—Vomiting—Hydrocortisone—psoriasis	9.64e-05	0.000379	CcSEcCtD
Mefloquine—Rash—Hydrocortisone—psoriasis	9.56e-05	0.000376	CcSEcCtD
Mefloquine—Dermatitis—Hydrocortisone—psoriasis	9.55e-05	0.000375	CcSEcCtD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.53e-05	0.00115	CbGpPWpGaD
Mefloquine—Confusional state—Methotrexate—psoriasis	9.51e-05	0.000374	CcSEcCtD
Mefloquine—Headache—Hydrocortisone—psoriasis	9.5e-05	0.000373	CcSEcCtD
Mefloquine—Dizziness—Triamcinolone—psoriasis	9.44e-05	0.000371	CcSEcCtD
Mefloquine—Anaphylactic shock—Methotrexate—psoriasis	9.43e-05	0.000371	CcSEcCtD
Mefloquine—Feeling abnormal—Prednisone—psoriasis	9.3e-05	0.000365	CcSEcCtD
Mefloquine—Asthenia—Betamethasone—psoriasis	9.3e-05	0.000365	CcSEcCtD
Mefloquine—Asthenia—Dexamethasone—psoriasis	9.3e-05	0.000365	CcSEcCtD
Mefloquine—Nervous system disorder—Methotrexate—psoriasis	9.25e-05	0.000363	CcSEcCtD
Mefloquine—Thrombocytopenia—Methotrexate—psoriasis	9.23e-05	0.000363	CcSEcCtD
Mefloquine—Gastrointestinal pain—Prednisone—psoriasis	9.23e-05	0.000363	CcSEcCtD
Mefloquine—Nausea—Prednisolone—psoriasis	9.22e-05	0.000362	CcSEcCtD
Mefloquine—Pruritus—Dexamethasone—psoriasis	9.17e-05	0.00036	CcSEcCtD
Mefloquine—Pruritus—Betamethasone—psoriasis	9.17e-05	0.00036	CcSEcCtD
Mefloquine—Skin disorder—Methotrexate—psoriasis	9.16e-05	0.00036	CcSEcCtD
Mefloquine—Hyperhidrosis—Methotrexate—psoriasis	9.12e-05	0.000358	CcSEcCtD
Mefloquine—Vomiting—Triamcinolone—psoriasis	9.08e-05	0.000357	CcSEcCtD
Mefloquine—ADORA2A—Circadian rythm related genes—JUN—psoriasis	9.08e-05	0.00109	CbGpPWpGaD
Mefloquine—Nausea—Hydrocortisone—psoriasis	9.01e-05	0.000354	CcSEcCtD
Mefloquine—Rash—Triamcinolone—psoriasis	9e-05	0.000354	CcSEcCtD
Mefloquine—Dermatitis—Triamcinolone—psoriasis	9e-05	0.000353	CcSEcCtD
Mefloquine—Urticaria—Prednisone—psoriasis	8.97e-05	0.000352	CcSEcCtD
Mefloquine—CYP19A1—Metabolism—CYP2S1—psoriasis	8.95e-05	0.00108	CbGpPWpGaD
Mefloquine—Headache—Triamcinolone—psoriasis	8.95e-05	0.000352	CcSEcCtD
Mefloquine—Abdominal pain—Prednisone—psoriasis	8.92e-05	0.000351	CcSEcCtD
Mefloquine—Body temperature increased—Prednisone—psoriasis	8.92e-05	0.000351	CcSEcCtD
Mefloquine—ADORA1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	8.87e-05	0.00107	CbGpPWpGaD
Mefloquine—Diarrhoea—Betamethasone—psoriasis	8.87e-05	0.000348	CcSEcCtD
Mefloquine—Diarrhoea—Dexamethasone—psoriasis	8.87e-05	0.000348	CcSEcCtD
Mefloquine—Hypotension—Methotrexate—psoriasis	8.81e-05	0.000346	CcSEcCtD
Mefloquine—BCHE—Metabolism—CYP2S1—psoriasis	8.69e-05	0.00105	CbGpPWpGaD
Mefloquine—Musculoskeletal discomfort—Methotrexate—psoriasis	8.59e-05	0.000338	CcSEcCtD
Mefloquine—Dizziness—Betamethasone—psoriasis	8.57e-05	0.000337	CcSEcCtD
Mefloquine—Dizziness—Dexamethasone—psoriasis	8.57e-05	0.000337	CcSEcCtD
Mefloquine—Insomnia—Methotrexate—psoriasis	8.53e-05	0.000335	CcSEcCtD
Mefloquine—Nausea—Triamcinolone—psoriasis	8.48e-05	0.000333	CcSEcCtD
Mefloquine—Paraesthesia—Methotrexate—psoriasis	8.47e-05	0.000333	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—TYK2—psoriasis	8.46e-05	0.00102	CbGpPWpGaD
Mefloquine—Dyspnoea—Methotrexate—psoriasis	8.41e-05	0.00033	CcSEcCtD
Mefloquine—Somnolence—Methotrexate—psoriasis	8.38e-05	0.000329	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—JUN—psoriasis	8.38e-05	0.00101	CbGpPWpGaD
Mefloquine—Hypersensitivity—Prednisone—psoriasis	8.31e-05	0.000327	CcSEcCtD
Mefloquine—Dyspepsia—Methotrexate—psoriasis	8.3e-05	0.000326	CcSEcCtD
Mefloquine—Vomiting—Betamethasone—psoriasis	8.24e-05	0.000324	CcSEcCtD
Mefloquine—Vomiting—Dexamethasone—psoriasis	8.24e-05	0.000324	CcSEcCtD
Mefloquine—Decreased appetite—Methotrexate—psoriasis	8.2e-05	0.000322	CcSEcCtD
Mefloquine—Rash—Dexamethasone—psoriasis	8.17e-05	0.000321	CcSEcCtD
Mefloquine—Rash—Betamethasone—psoriasis	8.17e-05	0.000321	CcSEcCtD
Mefloquine—Dermatitis—Betamethasone—psoriasis	8.16e-05	0.000321	CcSEcCtD
Mefloquine—Dermatitis—Dexamethasone—psoriasis	8.16e-05	0.000321	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Methotrexate—psoriasis	8.14e-05	0.00032	CcSEcCtD
Mefloquine—Fatigue—Methotrexate—psoriasis	8.13e-05	0.000319	CcSEcCtD
Mefloquine—Headache—Betamethasone—psoriasis	8.12e-05	0.000319	CcSEcCtD
Mefloquine—Headache—Dexamethasone—psoriasis	8.12e-05	0.000319	CcSEcCtD
Mefloquine—Asthenia—Prednisone—psoriasis	8.1e-05	0.000318	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	8.06e-05	0.000971	CbGpPWpGaD
Mefloquine—Pruritus—Prednisone—psoriasis	7.98e-05	0.000314	CcSEcCtD
Mefloquine—Feeling abnormal—Methotrexate—psoriasis	7.77e-05	0.000305	CcSEcCtD
Mefloquine—ADORA1—Circadian rythm related genes—TP53—psoriasis	7.76e-05	0.000935	CbGpPWpGaD
Mefloquine—Diarrhoea—Prednisone—psoriasis	7.72e-05	0.000303	CcSEcCtD
Mefloquine—Gastrointestinal pain—Methotrexate—psoriasis	7.71e-05	0.000303	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—IFNG—psoriasis	7.71e-05	0.000928	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	7.7e-05	0.000927	CbGpPWpGaD
Mefloquine—Nausea—Dexamethasone—psoriasis	7.7e-05	0.000302	CcSEcCtD
Mefloquine—Nausea—Betamethasone—psoriasis	7.7e-05	0.000302	CcSEcCtD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	7.69e-05	0.000926	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCL20—psoriasis	7.59e-05	0.000913	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	7.55e-05	0.000909	CbGpPWpGaD
Mefloquine—Urticaria—Methotrexate—psoriasis	7.49e-05	0.000294	CcSEcCtD
Mefloquine—Dizziness—Prednisone—psoriasis	7.46e-05	0.000293	CcSEcCtD
Mefloquine—Abdominal pain—Methotrexate—psoriasis	7.46e-05	0.000293	CcSEcCtD
Mefloquine—Body temperature increased—Methotrexate—psoriasis	7.46e-05	0.000293	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	7.32e-05	0.000881	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	7.27e-05	0.000875	CbGpPWpGaD
Mefloquine—Vomiting—Prednisone—psoriasis	7.18e-05	0.000282	CcSEcCtD
Mefloquine—ABCB1—Allograft Rejection—CXCL8—psoriasis	7.17e-05	0.000863	CbGpPWpGaD
Mefloquine—Rash—Prednisone—psoriasis	7.12e-05	0.00028	CcSEcCtD
Mefloquine—Dermatitis—Prednisone—psoriasis	7.11e-05	0.000279	CcSEcCtD
Mefloquine—ADORA1—Circadian rythm related genes—IL6—psoriasis	7.11e-05	0.000855	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—ACE—psoriasis	7.1e-05	0.000855	CbGpPWpGaD
Mefloquine—Headache—Prednisone—psoriasis	7.07e-05	0.000278	CcSEcCtD
Mefloquine—Hypersensitivity—Methotrexate—psoriasis	6.95e-05	0.000273	CcSEcCtD
Mefloquine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	6.85e-05	0.000825	CbGpPWpGaD
Mefloquine—Asthenia—Methotrexate—psoriasis	6.77e-05	0.000266	CcSEcCtD
Mefloquine—ADORA1—GPCR ligand binding—CXCL8—psoriasis	6.76e-05	0.000814	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	6.72e-05	0.000809	CbGpPWpGaD
Mefloquine—Nausea—Prednisone—psoriasis	6.7e-05	0.000263	CcSEcCtD
Mefloquine—Pruritus—Methotrexate—psoriasis	6.67e-05	0.000262	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	6.6e-05	0.000794	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—NFKB1—psoriasis	6.59e-05	0.000793	CbGpPWpGaD
Mefloquine—Diarrhoea—Methotrexate—psoriasis	6.45e-05	0.000254	CcSEcCtD
Mefloquine—BCHE—Metabolism of proteins—ACE—psoriasis	6.34e-05	0.000763	CbGpPWpGaD
Mefloquine—Dizziness—Methotrexate—psoriasis	6.24e-05	0.000245	CcSEcCtD
Mefloquine—Vomiting—Methotrexate—psoriasis	6e-05	0.000236	CcSEcCtD
Mefloquine—ADORA2A—Circadian rythm related genes—TP53—psoriasis	5.99e-05	0.000722	CbGpPWpGaD
Mefloquine—Rash—Methotrexate—psoriasis	5.95e-05	0.000234	CcSEcCtD
Mefloquine—Dermatitis—Methotrexate—psoriasis	5.94e-05	0.000233	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—STAT3—psoriasis	5.92e-05	0.000713	CbGpPWpGaD
Mefloquine—Headache—Methotrexate—psoriasis	5.91e-05	0.000232	CcSEcCtD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	5.9e-05	0.000711	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCL20—psoriasis	5.86e-05	0.000705	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—VEGFA—psoriasis	5.82e-05	0.000701	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	5.66e-05	0.000681	CbGpPWpGaD
Mefloquine—Nausea—Methotrexate—psoriasis	5.6e-05	0.00022	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—TP53—psoriasis	5.53e-05	0.000666	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—IL6—psoriasis	5.49e-05	0.00066	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	5.38e-05	0.000648	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR ligand binding—CXCL8—psoriasis	5.22e-05	0.000628	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.11e-05	0.000615	CbGpPWpGaD
Mefloquine—ABCB1—Allograft Rejection—TNF—psoriasis	4.99e-05	0.000601	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NDUFA5—psoriasis	4.99e-05	0.0006	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.99e-05	0.0006	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	4.96e-05	0.000597	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CARM1—psoriasis	4.76e-05	0.000573	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NDUFA5—psoriasis	4.7e-05	0.000566	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.69e-05	0.000565	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	4.63e-05	0.000558	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.55e-05	0.000548	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.45e-05	0.000535	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	4.42e-05	0.000532	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—LEP—psoriasis	4.41e-05	0.000531	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CARM1—psoriasis	4.37e-05	0.000526	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CARM1—psoriasis	4.24e-05	0.000511	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP2S1—psoriasis	4.24e-05	0.000511	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SOCS1—psoriasis	4.18e-05	0.000503	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—IL6—psoriasis	4.14e-05	0.000498	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	4.09e-05	0.000492	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP2S1—psoriasis	4e-05	0.000481	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—TYK2—psoriasis	3.98e-05	0.00048	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.97e-05	0.000478	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—LEP—psoriasis	3.94e-05	0.000474	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—CXCL8—psoriasis	3.82e-05	0.00046	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—CXCL8—psoriasis	3.47e-05	0.000418	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	3.29e-05	0.000396	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SOCS1—psoriasis	3.23e-05	0.000388	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.16e-05	0.000381	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—APOE—psoriasis	3.08e-05	0.000371	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—LEP—psoriasis	3.08e-05	0.000371	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—TYK2—psoriasis	3.08e-05	0.00037	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NDUFA5—psoriasis	3.07e-05	0.00037	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—CXCL8—psoriasis	2.95e-05	0.000355	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—CXCL8—psoriasis	2.93e-05	0.000353	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CAT—psoriasis	2.93e-05	0.000352	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NFKBIA—psoriasis	2.87e-05	0.000346	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.87e-05	0.000346	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CAT—psoriasis	2.69e-05	0.000324	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—CXCL8—psoriasis	2.68e-05	0.000322	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—CXCL8—psoriasis	2.62e-05	0.000315	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP2S1—psoriasis	2.61e-05	0.000315	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CAT—psoriasis	2.61e-05	0.000314	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.46e-05	0.000296	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—APOE—psoriasis	2.38e-05	0.000287	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—LEP—psoriasis	2.38e-05	0.000287	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TYK2—psoriasis	2.35e-05	0.000283	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—APOE—psoriasis	2.27e-05	0.000274	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NFKBIA—psoriasis	2.22e-05	0.000267	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.17e-05	0.000261	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—APOE—psoriasis	2.09e-05	0.000252	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CARM1—psoriasis	2.07e-05	0.000249	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CXCL8—psoriasis	2.05e-05	0.000247	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—APOE—psoriasis	2.03e-05	0.000244	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PPARG—psoriasis	1.98e-05	0.000238	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CARM1—psoriasis	1.95e-05	0.000235	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL6—psoriasis	1.95e-05	0.000235	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—JUN—psoriasis	1.9e-05	0.000229	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NFKB1—psoriasis	1.83e-05	0.000221	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PPARG—psoriasis	1.82e-05	0.000219	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TYK2—psoriasis	1.82e-05	0.000219	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PPARG—psoriasis	1.77e-05	0.000213	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—VEGFA—psoriasis	1.66e-05	0.0002	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—STAT3—psoriasis	1.65e-05	0.000198	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCL8—psoriasis	1.58e-05	0.00019	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL6—psoriasis	1.5e-05	0.000181	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JUN—psoriasis	1.47e-05	0.000177	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NFKB1—psoriasis	1.42e-05	0.00017	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—VEGFA—psoriasis	1.28e-05	0.000155	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CARM1—psoriasis	1.28e-05	0.000154	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CAT—psoriasis	1.27e-05	0.000153	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—STAT3—psoriasis	1.27e-05	0.000153	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—psoriasis	1.26e-05	0.000151	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CAT—psoriasis	1.2e-05	0.000145	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL6—psoriasis	1.15e-05	0.000139	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—APOE—psoriasis	9.9e-06	0.000119	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—psoriasis	9.71e-06	0.000117	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—APOE—psoriasis	9.33e-06	0.000112	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL6—psoriasis	8.89e-06	0.000107	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PPARG—psoriasis	8.62e-06	0.000104	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PPARG—psoriasis	8.12e-06	9.78e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CAT—psoriasis	7.85e-06	9.45e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—APOE—psoriasis	6.1e-06	7.34e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PPARG—psoriasis	5.31e-06	6.39e-05	CbGpPWpGaD
